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Background: Detailed comparison of effectiveness between organised and opportunistic mammography screening
operating in the same country has seldom been carried out.
Patients and methods: Prognostic indicators, as defined in the European Guidelines, were used to evaluate
screening effectiveness in Switzerland. Matching of screening programmes’ records with population-based cancer
registries enabled to compare indicators of effectiveness by screening and detection modality (organised versus
opportunistic screening, unscreened, interval cancers). Comparisons of prognostic profile were also drawn with two
Swiss regions uncovered by service screening of low and high prevalence of opportunistic screening, respectively.
Results: Opportunistic and organised screening yielded overall little difference in prognostic profile. Both screening
types led to substantial stage shifting. Breast cancer prognostic indicators were systematically more favourable in
Swiss regions covered by a programme. In regions without a screening programme, the higher the prevalence of
opportunistic screening, the better was the prognostic profile.
Conclusions: Organised screening appeared as effective as opportunistic screening. Mammography screening has
strongly influenced the stage distribution of breast cancer in Switzerland, and a favourable impact on mortality is
anticipated. Extension of organised mammography screening to the whole of Switzerland can be expected to further
improve breast cancer prognosis in a cost-effective way.
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introduction
Since effectiveness of high-quality mammography screening for
women aged 50 and over was proved in randomised controlled
trials, organised (service) and opportunistic (individual)
screening have become widespread throughout Europe [1, 2]. If
breast cancer mortality reductions reported in service screening
programmes have been consistent with those found in
randomised trials [3], no direct evidence yet supports the
effectiveness of opportunistic screening.
In most European countries, opportunistic and organised
screening coexist. Lower service screening attendance has
been observed in countries with simultaneous presence of
substantial opportunistic screening [4–7]. Apart from
different attendance rates, short-term performance indicators
of quality and early effectiveness reached similar levels in
programmes that operated in centralised and decentralised
health care systems [8]. Thus, mortality reductions
expected at a population level from programmes’ attendance
and performances only would be underestimated if
participation to, and effectiveness of, opportunistic screening
is not considered in those settings where both screening
modalities coexist.
The decentralised nature and lack of systematic and reliable
reporting of opportunistic mammography screening activity
have strongly limited the evaluation of its effectiveness.
Indeed, many series could not differentiate mammography
into diagnostic versus de facto opportunistic screening
[9, 10]. Thus, accurate comparison of effectiveness between
organised and opportunistic screening has seldom been
carried out.
This study was set up in Switzerland where the modality of
cancer diagnosis is reliably ascertained by registries [11] and the
distribution of organised versus opportunistic screening varies
substantially across regions. The two objectives were (i) to
compare breast cancer screening effectiveness in organised
versus opportunistic screening for different patterns of
screening attendance and (ii) to study the prognostic profile of
breast cancer in presence of low and high prevalence of
opportunistic screening.
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patients and methods
Five mammography screening programmes are operating in Switzerland,
covering all six French-speaking cantons (Swiss administrative units) and
25% of the Swiss female resident population aged 50–69 years. These
regional programmes have similar quality control and screening procedures
(eligibility, invitation) that include double reading with arbitration and
two-view mammography. Opportunistic screening is available throughout
the country, but mammography screening is only reimbursed when carried
out biennially from age 50 within an organised, quality-controlled
programme.
This study focussed primarily on the three Swiss cantons (Geneva, Vaud
and Valais) with the longest operating screening programmes. They all were
launched in the wake of the Swiss pilot project (1993–1998) [12], and data
on the first 8 years of operation were available for these analyses (1999–
2006). While self-reported use of mammography (screening and diagnostic)
among females aged 50–69 years was overall similar, 90%, in the three
cantons during this time period, participation widely differed across
programmes (Geneva: 26%, Vaud: 49%, Valais: 66%) [13]. This mainly
reflected a higher prevalence of opportunistic screening in cantons with
a lower programme’s participation.
Screening programmes’ records could be matched with cancer registries’
databases in Vaud and Valais only. However, all three cancer registries
included details on the modality of diagnosis (i.e. screening, symptoms).
Four categories of breast cancers were considered according to screening
and detection method: (i) screen-detected cancer by organised screening
(registry-ascertained cancer detected by mammography screening
programme), (ii) screen-detected cancer by opportunistic screening
(registry-ascertained, screen-detected cancer with no organised
mammography in the last 2 years), (iii) interval cancer (registry-ascertained
cancer with a screen-negative organised mammography in the last 2 years)
and (iv) unscreened cases (cancer diagnosed via symptoms among
nonparticipants in the last 2 years of the programme).
Performance and prognostic indicators as defined in the European
Guidelines [14] were used to assess screening effectiveness. Prognostic
indicators were computed for each screening/detection modality
(intracantonal comparisons for Vaud and Valais), as well as for the whole
cantons (intercantonal comparisons). Comparisons across cantons
included two additional regions covered by a Cancer Registry with low (St
Gallen, 30%) and high (Ticino, 70%) prevalence of opportunistic
screening, but without organised screening programme. Data collection was
completed at the end of 2007. As the three screening programmes started
during 1999 and interval cancers need a 2-year follow-up to be exhaustively
identified, intercantonal comparisons pertained to the 2000–2005 time
period. Comparisons of breast cancer prognosis within and between
cantons relied on clinical characteristics of cancers routinely notified to
registries. Age was taken at cancer diagnosis (50–69).
results
Table 1 provides selected indicators of screening quality for the
195 561 screens carried out over the 1999–2006 time period in
the Geneva, Vaud and Valais programmes. European norms
were met for initial and subsequent rounds except the slightly
exceeding recall rate in prevalent screen in Geneva and Valais
(target: 7.0%). The recall rate was the indicator with the largest
variation across programmes (6.4%–7.9% for prevalent round
and 3.3%–4.8% for incident round).
Indicators of effectiveness by detection and screening
modality are shown in Table 2 for Vaud and Table 3 for Valais,
for women aged 50–69 years at diagnosis. International
standards of effectiveness were reached for screen-detected
cancers in both programmes. Half the reported cancers in these
cantons were screen detected (Vaud: 51%, Valais: 53%), and
screen detection occurred twice as often through organised
than opportunistic screening.
Opportunistic and organised screening afforded a similar
prognostic profile in Vaud (Table 2). In Valais, opportunistic
screening was associated with a slightly more favourable
prognostic profile (Table 3). Results consistently pointed
towards an earlier detection of breast cancers in Vaud than
Valais, whether within the programme or opportunistically.
The prognostic profile was worst for unscreened (symptomatic)
cases. In terms of prognosis, interval cancers fared slightly
better than breast cancers diagnosed among unscreened
subjects but were at a more advanced stage than screen-
detected tumours.
Breast cancer prognostic indicators were systematically more
favourable in cantons with than without a mammography
screening programme (Table 4). For instance, the proportion of
Table 1. Selected indicators of performance in Swiss regional screening
programmes (GE, VD and VS), women aged 50–69 years, 1999–2006
Performance indicator GE,
n = 38 506
VD,
n = 104 166
VS,
n = 52 889
Recall rate (%)
Initial screen 7.9 6.4 7.1
Subsequent screen 4.8 3.9 3.3
Benign to malignant biopsy ratio
Initial screen n.a 0.47 0.55
Subsequent screen n.a 0.28 0.24
Breast cancer detection rate
Initial screen 6.1 7.6 6.2
Subsequent screen 5.9 5.9 4.8
Interval cancers (initial screen,
proportional incidence)
0–11 months after screening 22.7 24.0 27.3
12–23 months after screening 51.3 41.9 53.2
GE, Geneva; VD, Vaud; VS, Valais; n.a., not available.
Table 2. Distribution of prognostic indicators for breast cancer by
detection and screening modality in the canton of Vaud, 2000–2005
(women aged 50–69 years at cancer diagnosis)
Prognostic
indicatorsa
(%)
Participants Nonparticipantsb
Screen
detected,
n = 488
Interval
cancers,
n = 133
Screened,
n = 241
Unscreened,
n = 560
In situ 18.9 9.0 22.4 3.6
£1 cm 43.3 25.0 39.7 17.7
£2 cm 83.2 71.6 84.4 54.6
Stage ‡ II 28.8 44.8 27.5 43.7
Node negative 72.0 58.6 73.0 58.5
aExcept for the % percentage of in situ cases, indicators are based on
invasive cancers only.
bIncludes former participants for which the cancer was diagnosed >2 years
after the last mammography test.
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invasive cancers £10 mm was nearly thrice as low in St Gallen
(screening coverage of 30%, entirely opportunistic) than in
Vaud (screening coverage of 80% with 30% opportunistic
screening as well). In the absence of organised screening, the
higher the prevalence of opportunistic screening, the more
favourable breast cancer prognosis was documented.
discussion
Organised screening was found to be as effective as opportunistic
screening in regions covered by mammography screening
programmes, a finding that few studies have been able to
explore. Further, the positive association observed between
prognostic indicators and prevalence of opportunistic screening
in regions without screening programmes was strongly
suggestive of the effectiveness of opportunistic screening.
These observations occurred in a setting, Switzerland, where
European standards for screening effectiveness were met by
organised programmes. Results were consistent across three
regions with overall comparable proportions of target
population covered by screening, but irrespective of the
different attendance rates in these regional screening
programmes (respectively, high, moderate and low). Although
acceptable levels of performance indicators do not necessarily
warrant a decrease in breast cancer mortality [15], the
favourable stage shifting observed, particularly in cantons with
organised screening programmes, augurs a screen-attributable
decline in breast cancer mortality in these regions.
Two strengths of this study were the ability to separate
diagnostic from opportunistic mammography on medical files
and to accurately match programme-based screening and breast
cancer records in these populations. However, some degree of
misclassification of the modality of cancer diagnosis could not
totally be avoided. On the one hand, opportunistic screening is
not reimbursed by basic, compulsory health insurance in
Switzerland but diagnostic screening is. Therefore, some
asymptomatic patients might thus have been referred as having
clinical symptoms to ensure health insurance coverage for the
woman. Evidence to support this assumption was unavailable
but such medical behaviour would probably underestimate the
effectiveness of opportunistic screening since symptomatic
cases likely correspond to more advanced lesions. On the other
hand, anecdotic evidence indicated that a few symptomatic
women attended the screening programmes to benefit from the
cost-free examination. Excluding these women from the study
would have required the systematic recording of their
symptomatology.
Some variations in screening effectiveness were found between
Swiss regional programmes. Although a detailed examination of
the reasons underpinning these variations are beyond the scope
of this paper, complementary analyses hint to differences in
multiple reading strategy and minimum reading volume
requirements as the most likely explanations. Vaud and Geneva
programmes had similar radiological procedures and showed
similar prognostic profile for breast cancers. Thus, the uptake in
organised versus opportunistic mammography screening in
these three cantons should not explain the slight, regional
variations in organised screening effectiveness. A recent Danish
study reported a considerably higher sensitivity in organised
than opportunistic screening but similar specificity for both
screening modalities [10]. How these different radiological
performances will translate into effectiveness of organised and
opportunistic mammography screening is yet to be quantified.
Heterogeneity in access to care and quality of treatment
cannot be ruled out to explain some of the variations in breast
cancer prognosis across Switzerland. Substantial differences in
mortality trends predating the widespread use of
mammography screening have been reported within
Switzerland [16], as well as regional differences in breast cancer
survival [17]. These studies support not only a better breast
cancer diagnosis but also management in areas where organised
screening has been implemented.
The major differences between opportunistic and organised
screening in Switzerland lie in the frequency of the test (often
annually for the former) and the inclusion of immediate,
Table 3. Distribution of prognostic indicators for breast cancer by
detection and screening modality in the canton of Valais, 2000–2005
(women aged 50–69 years at cancer diagnosis)
Prognostic
indicatorsa
(%)
Participants Nonparticipantsb
Screen
detected,
n = 259
Interval
cancers,
n = 89
Screened,
n = 137
Unscreened,
n = 256
In situ 10.8 5.6 13.1 5.5
£2 cmc 75.8 54.7 79.7 51.2
Stage ‡ II 40.5 58.5 31.6 64.7
Node negative 69.6 58.5 81.0 54.0
aExcept for the % percentage of in situ cases, indicators are based on
malignant cancers only.
bIncludes former participants for which the cancer was diagnosed >2 years
after the last mammography test.
cpT stage was not directly available from the Valais Cancer Registry.
Construction of this information was based on clinical and pathological
data which did not allow to reliably estimate the percentage of malignant
cases £1 cm (pT1a or pT1b).
Table 4. Prognostic indicators for breast cancer in Swiss cantons with
and without a screening programme and according to prevalence of
opportunistic screening (SG: low, TI: high), 2000–2005 (women aged 50–
69 years at cancer diagnosis)
Prognostic
indicatorsa
(%)
Cantons with screening
programmes
Cantons without
screening programmes
VS,
n = 741
VD,
n = 1422
GE,
n = 921
SG,
n = 686
TI,
n = 721
In situ 8.5 12.5 13.7 9.3 5.8
£1 cm –b 30.1 26.1 10.9 18.2
£2 cm 64.2 70.1 70.4 49.6 63.5
Stage ‡ II 46.4 36.4 47.0 65.5 56.5
Node negative 67.2 65.2 67.1 56.0 55.4
aExcept for the percentage of in situ cases, indicators are based on malignant
cancers only.
bpT stage was not directly available and was reconstructed on the basis of
clinical and pathological data from the Valais Cancer Registry.
VS, Valais; VD, Vaud; GE, Geneva; SG, St Gallen; TI, Ticino.
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additional investigations (three views per breast, ultrasound)
when deemed necessary in opportunistic screening. Such
differences should improve effectiveness of opportunistic
screening alone, though in a non-cost-effective manner [18].
Compulsory, quality-controlled procedures for organised
screening do not systematically apply to opportunistic
screening, whereas the same radiologists generally carry out
opportunistic and organised screening mammography with the
same equipment in Switzerland. One may assume
opportunistic screening to benefit from the training of
radiographers, higher reading volume of radiologists and the
technical, quality-controlled procedures.
The findings that high-quality mammography service
screening can yield similar effectiveness as opportunistic screen
warrants that extension of organised mammography screening
to the whole of Switzerland should be a cost-effective measure.
Comparisons of cost-effectiveness between various scenarios of
attendance and coexistence for both screening modalities in
Switzerland are under way [18].
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